Q2 2026 Palatin Technologies Inc Earnings Call Transcript
Key Points
- Palatin Technologies Inc (PTN) successfully completed an $18.2 million public offering, strengthening its balance sheet and restoring its NYSE American listing.
- The company is advancing its melanocortin-4 receptor-based obesity pipeline, targeting rare neuroendocrine obesity disorders such as hypothalamic obesity and Prader-Willi syndrome.
- Palatin Technologies Inc (PTN) has a cash runway extending beyond March 31, 2027, providing financial stability for ongoing projects.
- The company received $3.8 million in upfront consideration from the sublicensing of PL9643, enhancing its focus on core obesity programs.
- Palatin Technologies Inc (PTN) is exploring the potential for coadministration of melanocortin-4 receptor agonists with GLP-1-based therapeutics, offering flexibility in evolving obesity treatment paradigms.
- Palatin Technologies Inc (PTN) reported a net loss of $7.3 million for the second quarter, a significant increase from the $2.4 million loss in the same period last year.
- Operating expenses rose to $7.4 million, up from $2.6 million in the prior year, due to higher investment in obesity development programs and increased compensation costs.
- Revenue for the quarter was only $116,000, reflecting limited income from cost reimbursement under a collaboration agreement.
- There is no assurance that the Series J warrants from the recent public offering will be exercised, potentially limiting additional capital inflow.
- The company faces risks and uncertainties related to the development and approval of its obesity treatments, which could impact future performance.
Greetings. Welcome to Palatin's second quarter fiscal year 2026 operating results conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements.
These statements are based on assumptions that may or may not prove to be accurate and that the actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission.
Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatin's prospects. Now I would like to turn the call over to our host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.
Thank you, and good morning, everyone. Earlier today, we reported Palatin's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
